185 related articles for article (PubMed ID: 37496366)
1. Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors.
Passey C; Voellinger J; Gibiansky L; Gunawan R; Nicacio L; Soumaoro I; Hanley WD; Winter H; Gupta M
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1262-1273. PubMed ID: 37496366
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
3. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
4. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
5. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori K; Kuboki Y; Hasegawa K; Iwata T; Kato H; Takehara K; Hirashima Y; Kato H; Passey C; Buchbjerg JK; Harris JR; Andreassen CM; Nicacio L; Soumaoro I; Fujiwara K
Cancer Sci; 2022 Aug; 113(8):2788-2797. PubMed ID: 35633184
[TBL] [Abstract][Full Text] [Related]
6. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
8. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
9. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
10. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A; Mould DR; Song G; Collins GP; Endres CJ; Gomez-Navarro J; Venkatakrishnan K
Clin Pharmacol Ther; 2019 Dec; 106(6):1268-1279. PubMed ID: 31152605
[TBL] [Abstract][Full Text] [Related]
12. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
13. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
Li H; Han TH; Hunder NN; Jang G; Zhao B
J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.
Cleary JM; Calvo E; Moreno V; Juric D; Shapiro GI; Vanderwal CA; Hu B; Gifford M; Barch D; Roberts-Rapp L; Ansell PJ; Xiong H; Ocampo C; Tolcher AW
Invest New Drugs; 2020 Oct; 38(5):1483-1494. PubMed ID: 32189093
[TBL] [Abstract][Full Text] [Related]
20. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]